Merck KGaA's Erbitux Receives EMA Approval for Targeted Treatment of Colorectal and Head and Neck Cancers
Strengthening Presence in the European Market for Targeted Cancer Therapies
Erbitux (cetuximab), a targeted anticancer drug developed by Merck Europe B.V., a subsidiary of Merck KGaA (MRK.DE), has received marketing authorization from the European Medicines Agency (EMA), establishing it as a key drug in the European anticancer market. The drug works by blocking the epidermal growth factor receptor (EGFR), which is overexpressed on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. In 2024, Merck KGaA recorded global sales of EUR 1.162 billion from Erbitux alone, maintaining its status as a solid blockbuster drug. Recent additions to clinical data and expansion of indications have provided an opportunity to further solidify its position in the European market.
Establishing a Standard for Patient-Specific Precision Medicine
Erbitux is prescribed for the treatment of metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN) in patients who have EGFR expression and a wild-type RAS gene. Because the drug's efficacy has only been proven in patients without gene mutations, RAS mutation status must be confirmed through companion diagnostics before prescription. This regulatory approval process has played a crucial role in establishing precision medicine, which minimizes unnecessary side effects and maximizes treatment efficacy in clinical practice. As a result, it provides positive value to both regulatory agencies seeking to streamline drug costs and patients.
Global Competitive Landscape and Comparison with Amgen's Vectibix
Erbitux's strongest competitor is Vectibix (panitumumab) from Amgen (AMGN), which shares the same EGFR target and competes fiercely in the market. Erbitux is a chimeric IgG1 antibody with both mouse and human-derived regions, while Vectibix is a fully human IgG2 antibody, representing a structural difference. The ASPECCT Phase 3 study demonstrated non-inferiority between the two drugs, but Erbitux has high trust in clinical practice based on extensive clinical data on combination therapy with existing chemotherapy. Recently, it has also obtained approval for combination therapy with Braftovi (encorafenib) from Pfizer (PFE), opening up new avenues.
Commercial Value in the $15 Billion Colorectal Cancer Market
The global market for metastatic colorectal cancer treatments is approximately $13 billion to $15 billion (USD) as of 2025/2026, with a stable annual growth rate of 4.6% to 5.9%. In the second quarter of 2025, Erbitux showed organic sales growth of 10.9%, and in the third quarter, 10.3%, demonstrating that it continues to play a key role in Merck's cash cow, despite concerns about patent expiration. While the entry of biosimilars and new competitive pipelines, such as combination therapy with immune checkpoint inhibitors, are expected in the future, it is expected to be able to defend its sales in the long term thanks to the clinical database established as a standard of care.
The EMA approval and expanded indications for Erbitux are key factors in demonstrating Merck KGaA's ability to defend its oncology pipeline revenue in the approximately $13 billion to $15 billion metastatic colorectal cancer treatment market. In particular, despite the non-inferiority competition with Amgen's Vectibix, it is developing new combination therapies with other companies' targeted therapies, such as Pfizer's Braftovi, and diversifying indications through Phase 3 studies. This provides a standard for genomic-based precision medicine combinations, beyond a simple first-line treatment, and suggests the direction of development for combination therapies using EGFR inhibitors in various cancers for those in the clinical and bio industries. As a result, despite concerns about the entry of biosimilars due to patent expiration, it is expected to maintain its market dominance in the medium to long term based on diversified combination indications and high prescription trust, and will continue to contribute to the stability of the company's cash flow.
Source: EMA (ema)